Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 13/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746073 | 0.76 | CTSA (0.51) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL1172432 | 0.76 | CTSA (0.51) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL12879201 | 0.74 | CYP1A2 (0.48) | SMN1; SMN2CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12826507 | 0.73 | NR1H4 (0.51) | SMN1; SMN2MAPK1CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL197506 | 0.73 | CYP19A1 (0.64) | SMN1; SMN2TSHRCYP1A2CYP19A1CYP2C9 | |
| SCHEMBL14347947 | 0.69 | ALOX5 (0.53) | TSHRALOX5 | |
| SCHEMBL12653028 | 0.69 | LTA4H (0.61) | SMN1; SMN2TSHRCYP1A2CYP19A1CYP2C9 | |
| SCHEMBL21834297 | 0.69 | MAOB (0.39) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL21834242 | 0.69 | MAOB (0.39) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL14066695 | 0.68 | CACNA1B (0.53) | SMN1; SMN2LMNATSHRALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | CONNECTICUT, UNIVERSITY OF | 2010-09-16 | — | — | US | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| WO-2009052320-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052319-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | SMN1; SMN2 4824/4885LMNA 4375/4885HPGD 524/4885 |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | FAAH, FAAH2, CNR2 | SMN1; SMN2 3355/4885LMNA 3975/4885HPGD 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.